GSK invests $750M in cancer research
GSK, the British pharmaceutical company, plans to invest nearly $750 million to acquire rights to develop an experimental cancer treatment developed by Chinese company Chimigen Biosciences. The therapy is based on a T-cell activation technique that stimulates the immune system to attack cancer cells, while also reducing the side effects of treatment. The company intends to initiate Phase I clinical trials in 2027, with the possibility of increasing the deal’s value to $750 million depending on successful development milestones and regulatory approvals. The therapy focuses on treating multiple myeloma, a type of blood cancer.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading